<p class="abstract"><strong>Background:</strong> Vitiligo is a long-term skin disease identified by spots of the skin missing their pigment. The spots of skin changed turn white and usually have distinctive perimeters. The hairs that exist on the skin may also turn white due to this disease. Patients inside of the mouth and nose may also be affected by vitiligo. The objective of the study was to analyze results of using 308 nm excimer laser combined with tacrolimus 0.1% ointment for treating the patients associated with localized vitiligo.</p><p class="abstract"><strong>Methods:</strong> This research adopted a mixed method consisting a qualitative approach, a survey of related articles from renowned journals. Regarding data collected from patient’s database who underwent treatment at BSMMU, Bangladesh. Patients are divided into 3 groups. The first group included 30 vitiligo patients treated with topical 0.1% tacrolimus ointment applied twice daily for 10 weeks of follow-up. The second group consists of 30 vitiligo patients treated with 308 nm excimer laser applied three times a week for 10 weeks of follow-up. The third group of 30 vitiligo patients treated with 308 nm excimer laser combined tacrolimus 0.1% ointment applied twice daily for tacrolimus and three time a week for 308 nm excimer laser for 10 weeks).<strong></strong></p><p class="abstract"><strong>Results:</strong> The research result showed that the combined treatment of 308 nm excimer laser with 0.1% tacrolimus ointment and 308 nm excimer laser monotherapy are effective, reliable and well tolerated for the vitiligo treatment.</p><p class="abstract"><strong>Conclusions:</strong> The research result confirms the efficacy of excimer laser therapy in vitiligo patients, suggesting that an association with 0.1% tacrolimus may represent an advance in the treatment of the disease.</p>
<p class="abstract">Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease characterized by the recurrence of transient wheals, angioedema or both lasting for more than 6 weeks duration. Omalizumab is a newer humanized anti IgE immunoglobulin along with many new antibody treatments has shown beneficial effect in treatment of chronic spontaneous urticaria. Although many randomized clinical trials have been conducted, as of now, the effectiveness of omalizumab in the real world management of CSU is largely unknown. A systematic review of all studies should be done. The objective was to study the efficacy and safety of different doses of omalizumab in the treatment of chronic spontaneous urticaria which was refractory to treatment with H1 antihistamines. Suitable studies were recognized after searching Wiley online library, PubMed, Google scholar, NEJM/NEJ dermatology, JAAD, JACI, clinicaltrials.gov. Only randomized, double-blind, placebo-controlled clinical trials with omalizumab versus antihistamine or leukotriene antagonists as placebo were involved in this study. 10 randomized, placebo-controlled studies were involved with 1692 patients with CSU. Patients treated with omalizumab (75-600 mg every 4 weeks) had reduced UAS7 score, improved QoL (quality of life), reduced WISS, when compared to the placebo group. The effects of omalizumab were found to be dose dependent, with maximum reduction in UAS7 at a dose of 300 mg when given at an interval of 4 weeks’ duration. The incidences of adverse events were almost similar in both control and placebo groups and across various dose ranges. The best effect in reduction of clinical symptoms and QoL in CSU patients was found at a dose of 300 mg subcutaneous injection once a month of omalizumab for 12 to 24 weeks. Omalizumab was found to reduce the clinical symptoms and signs in patients with CSU who were symptomatic despite treatment with upscaling dose of H1 antihistamines.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.